Cosette's attempt to drop $438 million Mayne Pharma deal denied by court

Core Viewpoint - An Australian court has intervened to prevent Cosette Pharmaceuticals from abandoning its A$672 million ($437.6 million) acquisition of Mayne Pharma, indicating legal support for the transaction [1] Company Summary - Cosette Pharmaceuticals, a U.S. drugmaker, is involved in a significant acquisition deal valued at A$672 million ($437.6 million) for Mayne Pharma, an ASX-listed company [1] - The court's decision reflects the importance of this acquisition for both companies, potentially impacting their market positions and future strategies [1] Industry Summary - The pharmaceutical industry is witnessing increased scrutiny and legal involvement in major acquisition deals, highlighting the complexities and regulatory challenges faced by companies in this sector [1] - This case may set a precedent for future mergers and acquisitions within the pharmaceutical industry, particularly regarding cross-border transactions [1]